2024-12-13 11:30:51
Second, Contemporary Amperex Technology Co., Limited's enlargement trick: special dividends for factories in EuropeAmong them, the biggest benefit is the biomedical industry. It is necessary to set up a M&A fund with a scale of 10 billion, which is specifically aimed at the merger and reorganization of the biomedical industry! The focus is on local enterprises in Shanghai, especially the biomedicine of listed companies in Shanghai.Easy to change the world: shareholders intend to reduce their holdings by no more than 3.05% in total;
Say a data, since 2010, A shares have opened higher by more than 2% for 13 times, including 11 times of high opening and low walking, and only 2 times of high opening and high walking! Just get used to it, this is the urine of big A. Actually, it was good yesterday, which was in line with the slow cow. It is estimated that some people are still breathing a sigh of relief. If it rises like the beginning of October, they will not be able to sleep! You know, yesterday was a slow cow.China Research Institute: Wang Xiuyun reduced its shareholding by 1%. At present, the company has not directly involved in the application field of humanoid robots.Before, I said that institutions don't believe in bull market, but now I don't believe in many sizes, so investors are doing their best to support the stock market. Now every time it goes up, bosses of all sizes are reducing their holdings, including big funds, which are frequently cashed out ...! This will hit everyone's confidence in holding shares.
Contemporary Amperex Technology Co., Limited announced that the company plans to pay dividends with 15% of the net profit in the first three quarters of 2024, that is, 5.4 billion yuan as the total distribution, and distribute a cash dividend of 12.3 yuan to all shareholders for every 10 shares. In addition, Contemporary Amperex Technology Co., Limited and Stellantis plan to jointly set up a joint venture company in Spain, with each party holding 50% of the shares. The estimated total investment of the battery factory is 4.038 billion euros.Ningde's business in Europe has made progress. Through cooperation with local European giants, it has invested 30 billion RMB, with each party holding 50% of the shares. This is a new mode of exploring the sea! It is worth noting that this cooperation with Stellantis is mainly to supply lithium iron batteries and drive a new round of electrification in Europe through Ferrous lithium phosphate parity technology, which is a new opportunity from 0 to 1.Among them, the biggest benefit is the biomedical industry. It is necessary to set up a M&A fund with a scale of 10 billion, which is specifically aimed at the merger and reorganization of the biomedical industry! The focus is on local enterprises in Shanghai, especially the biomedicine of listed companies in Shanghai.
Strategy guide
12-13
Strategy guide
Strategy guide
12-13
Strategy guide 12-13